Metabolic risk with second-generation antipsychotic treatment: A double-blind randomized 8-week trial of risperidone and olanzapine

Annals of Clinical Psychiatry

Volumn 20, Issue 2, 2008, Pages 71-78

  Kelly, Deanna L ^a,d   Conley, Robert R ^a   Love, Raymond C ^b   Morrison, John A ^c   McMahon, Robert P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Lipids; Metabolic; Olanzapine; Risperidone; Schizophrenia; Weight

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG WITHDRAWAL; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; RISK; RISPERIDONE; SCHIZOPHRENIA; TRIGLYCERIDES; WEIGHT GAIN;

EID: 45949106124     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230802017050     Document Type: Article

References (38)

1. Abidi S, Bhaskara SM. From chlorpromazine to clozapine - antipsychotic adverse effects and the clinician's dilemma. Can J Psychiatry. 2003;48:749-755.
2. The Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998;59:17-22.
3. Wirshing DA, Pierre JM, Erhart SM, Boyd JA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am. 2003;26:165-190.
4. Beliard S, Valero R, Vialettes B. Atypical neuroleptics and diabetes. Diabetes Metab. 2003;3:296-299.
5. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26:1597-1605.
6. Tardieu S, Micallef J, Gentile S, Blin O. Weight gain profiles of new antipsychotics: public health consequences. Obes Rev. 2003;4:129-138.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in people with chronic schizophrenia. NEJM. 2005;353:1209-1223.
8. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
9. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-774.
10. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156:1686-1696.
11. Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther. 2003;25:1150-1171.
12. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone or olanzapine. Pharmacotherapy. 2003;23:1037-1043.
13. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-1139.
14. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revickci DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
15. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-1530.
16. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Zajecka J, Sundell KL, Kim Y, Beasley CM Jr. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170-1176.
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
18. Zeger SL, Liang KY. Data analyses for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
19. National Center for Health Statistics. Plan and operation of the third National Health and Nutrition Examination Survey, 1988-1994. Vital Health Stat. 1994;1:32.
20. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry. 1999;60:215-220.
21. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003;108:324-332.
22. Grundy SM, Pasternak R, Greeland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. Circulation. 1999;100:1481-1492.
23. Meyer JM. A retrospective comparison of weight, lipid and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
24. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacol. 2005;183:383-386.
25. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425-433.
26. McKenney JM. Update on the National Cholesterol Education Program adult treatment panel guidelines: getting to goal. Pharmacotherapy. 2003;23:26S-33S.
27. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:B7-B12.
28. Gaheli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy. 1999;19:1099-1101.
29. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Shizophr Res. 2004;66:51-57.
30. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Serv. 2003;54:565-567.
31. Russell JM, Mackell JA. Body weight associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs. 2001;15:537-551.
32. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR. The Mount Sinai conference on pharmacotherapy of schizophrenia. Schiz Bull. 2002;28:5-16.
33. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
34. Sudek CD, Kalyani RR, Derr RL. Assessment of glycemia in diabetes mellitus: Hemoglobin A1C. JAPI. 2005;53:299-305
35. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2007;30 (Suppl 1):S4-41.
36. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanism, management and research perspectives. Pharmacopsychiatry. 2002;35:205-219.
37. Risperidal. About Rispderdal. www.risperdal.com. Accessed March 17, 2005.
38. Zyprexa. Understanding Zyprexa. www.zyprexa.com. Accessed March 17, 2005.